Sign in to continue:

Saturday, March 7th, 2026

China Innovation Investment Limited Announces Board Meeting to Approve 2025 Final Results and Dividend on March 24, 2026 1

China Innovation Investment Limited Announces Upcoming Board Meeting

China Innovation Investment Limited Announces Board Meeting to Approve 2025 Final Results and Potential Dividend

Key Highlights for Investors

  • Board Meeting Scheduled: China Innovation Investment Limited (“the Company”) has scheduled a board meeting on Tuesday, 24 March 2026. This meeting will be critical as the board will deliberate on several important matters directly impacting shareholders.
  • Approval of Annual Results: The primary agenda is to consider and approve the final results for the financial year ended 31 December 2025. The release of annual results is a significant event that provides insights into the company’s financial health, business performance, and strategic direction.
  • Dividend Consideration: The board will also discuss the payment of a dividend (if any). The announcement or non-announcement of dividends is a price-sensitive issue that can have a direct impact on the company’s share price. Investors should pay close attention to this aspect, as dividend decisions reflect management’s outlook and cash flow strength.
  • Other Business Matters: The meeting will also address any other business items that may arise, which could potentially include strategic updates, changes in business operations, or other corporate actions.

Board and Management Structure

The current composition of the board includes:

  • Mr. Xiang Xin – Chairman and Chief Executive Officer
  • Mr. Chan Cheong Yee – Executive Director
  • Ms. An Jing – Independent Non-Executive Director
  • Ms. Zhou Zan – Independent Non-Executive Director
  • Ms. Qin Han – Independent Non-Executive Director
  • Ms. Kung Ching – Alternate Director to Mr. Xiang Xin

The continued leadership and oversight from an experienced board are crucial for the company’s governance and strategic execution.

Potential Price-Sensitive Information

  • The decision regarding the approval of the annual results and the payment of dividends are both potentially price-sensitive and of significant importance to shareholders. Any unexpected results or changes in dividend policy may influence investor sentiment and the market price of the company’s shares.
  • Investors should monitor the outcomes of this board meeting closely, as it is likely to provide important updates regarding the company’s performance and prospects for the coming year.

Conclusion

The upcoming board meeting of China Innovation Investment Limited on 24 March 2026 is an important event for all stakeholders. The approval of final results and dividend discussions could have a notable impact on the share price. Shareholders and potential investors are advised to stay alert for the company’s official announcements following the meeting.


Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are advised to conduct their own research or consult a professional advisor before making investment decisions. The information provided is based on public disclosures and may be subject to change.


View CH INNOVATION Historical chart here



HKC International Holdings Supplemental Announcement on 2025

HKC International Holdings Limited Issues Supplemental Announcement on Share Option Scheme HKC International Holdings Limited Issues Supplemental Announcement on Share Option Scheme Key Points from the Announcement Supplemental Information Released: HKC International Holdings Limited...

BlackRock Securities Dealings in ENN Energy Holdings Shares Amid Privatisation Scheme – March 2026 Disclosure

BlackRock, Inc. Disclosure in ENN Energy Holdings Ltd – Detailed Investor Update BlackRock, Inc. Makes Significant Share Dealings in ENN Energy Holdings Ltd Amid Privatisation Scheme Key Highlights from the Public Disclosure Date of...

Shanghai Fosun Pharmaceutical Announces Poll Results of 2026 EGM and Shareholders’ Meetings on Fosun Adgenvax Spin-off and Hong Kong Listing

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. – Poll Results of Key Resolutions at Extraordinary General Meetings (2026) Shanghai Fosun Pharmaceutical Announces Poll Results on Spin-off and Listing of Fosun Adgenvax Key Highlights from the...

   Ad